Brought to you by 
Biogen enters CNS R&D collaboration with Rodin with option to buy company; later ends deal
30 Jan 2023
Executive Summary
Biogen Inc., concurrent with a $17.3mm co-investment it made with Atlas Venture in Rodin Therapeutics Inc., is collaborating with the start-up to develop epigenetic modulators for CNS disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes M&A Option
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen enters CNS R&D collaboration with Rodin with option to buy company; later ends deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice